The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EARNINGS SUMMARY: Character Group Lowers Dividend As Profit Drops

Thu, 10th Dec 2020 17:07

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Character Group PLC - Surrey-based toymaker - For the year to the end of August, pretax profit more than halved to GBP5.0 million from GBP11.1 million the year before, on revenue that declined by 13% to GBP105.3 million from GBP120.4 million. Declares final dividend of 3.0 pence per share, bringing total payout to 5.0p, down 81% from 26.0p the year before.

----------

Artemis Alpha Trust PLC - listed companies investor aiming to outperform FTSE All-Share Index - Net asset value per share as at October 31 was down at 352.66 pence from 360.86p the same date the year before. Net asset value total return for the six-year period at 15%, compared to FTSE All-Share Index which fell by 2.0%.

----------

Evgen Pharma PLC - clinical stage drug development company based in Liverpool - For the six months to the end of September, pretax loss widens to GBP1.8 million from GBP1.6 million on higher operating costs, despite generating GBP194,000 in revenue from the upfront fee on the signing of the Juvenesence licensing deal.

----------

Securities Trust of Scotland PLC - Edinburgh-based investor - For the six months to the end of September, net asset value total return at 21%, compared to 12% the year before. Notes peer group returned 16% for the same period. As at September 30, net asset value per share at 195.58 pence, down from 203.88p the same date the prior year. Dividend per share down at 2.75p from 2.90p.

----------

Yellow Cake PLC - Jersey-based uranium investor - For the six months to the end of September, swings to pretax profit of USD21.7 million from loss of USD3.1 million the year before. Total uranium-related profit at USD23.5 million from loss of USD1.0 million. As at September 30, net asset value was USD279.9 million, comprising 9.32 million pounds of physical uranium at a spot price of USD29.75 per pound.

----------

Trafalgar Property Group PLC - residential homes developer based in Kent - For the six months to the end of September, swings to pretax profit of GBP17,000 from loss of GBP528,000 the year before, on revenue remaining flat at GBP1.3 million. Proposes consolidation shares on basis of one new share for every ten existing shares, increasing market price of new shares to 0.9p from 0.09p.

----------

C4X Discovery PLC - drug discovery firm - For the year to the end of July, pretax loss narrows to GBP9.6 million from GBP13.6 million the year before, due to fall in development and administrative expenses, in spite of no revenue being made. Looking ahead, plans to drive key drug discovery programmes to next milestone.

----------

DWF Group PLC - Manchester-based law firm - For the six months to the end of October, swings to pretax loss of GBP11.0 million from profit of GBP8.0 million the year before, due to non-cash acquisition-related costs, in spite of revenue growing by 15% to GBP167.6 million from GBP145.2 million. Declares dividend per share of 1.50 pence, up from 1.25p the prior year.

----------

Iconic Labs PLC - media company - For the year to the end of June, pretax loss widens to GBP2.8 million from GBP2.1 million the 18-month period before, on substantially higher administrative expenses, despite generating GBP107,303 in revenue through management services contracts.

----------

The Income & Growth Trust PLC - investment firm - As at September 30, net asset value per share down at 59.50 pence from 75.50p the same date the year before. For the annual period, declares dividend of 14.00 pence per share, more than doubled from 6.00p

----------

Oryx International Growth Fund Ltd - small and medium-sized business investor - Net asset value per share as at September 30 was 172.17 pence, up from 124.87p at the end of March. As at September 30 total value of investments was at GBP160.6 million from GBP117.3 million at the end of March.

----------

Cohort PLC - defence and security markets-focussed technology company - Says pretax loss for the six months to October 31 widens to GBP370,000 from GBP3,000 a year before. Revenue dips to GBP54.4 million from GBP60.2 million. Says it expects a "a much stronger performance in the second half", though it still needs to win and deliver some important orders to achieve its targets for the year.

----------

Majedie Investments PLC - London-based investment trust - Net asset value per share at September 30 was 247.7 pence, down 15% from 292.3p. Pretax loss for the year ended September 30 widens to GBP17.6 million from GBP16.5 million a year before. Declares final dividend of 11.40p, following suit to the prior year, having used its revenue reserves to maintain the payout despite its poor performance. Says that the improved performance in the second half is encouraging.

----------

Edinburgh Worldwide Investment Trust PLC - the Edinburgh-based investing company which typically invests in companies with a market capitalisation of less than USD5 billion at the time of first investment - Net asset value per share at October 31 at 279.90 pence, up 58% from 177.37p a year prior. Net return before tax for the year ended October 31 at GBP322.0 million, up from GBP33.4 million a year before. Says net revenue return per share is at negative 0.46p, up from negative 0.23p a year prior, so no final dividend is being paid. Says that going forward there is a lot of uncertainty with regards to the pandemic and Brexit.

----------

FastForward Innovations Ltd - Guernsey-based closed-ended investment company - Says investment gains in the six months to September 30 are down 12% to GBP1.5 million from GBP1.7 million a year prior. Net asset value per share at September 30 is up 6.9% to 9.43 pence from 8.82 pence a year before. Says it has seen varying performances across its portfolio of investee companies. "However, reflective of our new investing policy implemented in July, the liquidity of our portfolio is becoming more balanced and a number of our investments have performed very well during this period of uncertainty," the company says. Does not propose an interim dividend, following suit to the prior year.

----------

Induction Healthcare Group PLC - London-based healthcare technology company - Posts pretax loss for the half year ended September 30 of GBP3.2 million, widening 45% from GBP2.2 million a year prior. Revenue debuts at GBP582,000 from nothing the year before. Says in the last six months "we have continued to execute our 'buy and build' strategy successfully, evidenced by the Zesty acquisition in June". Joint Chief Executives Hugo Stephenson and James Balmain say: "Not only have we generated our first full year of revenues, we are seeing revenue growth across all of our platforms". Says, going forward, that sales momentum, recurring revenue, our pipeline of orders with multi-year contracts, and a healthy acquisition pipeline provide a foundation for future growth.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com and Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
24 Jun 2016 09:49

WINNERS & LOSERS SUMMARY: Gold, Dollar Exposure Rewarded Post-Brexit

Read more
31 May 2016 09:59

Evgen Pharma Pleased With "Significant Progress" Since AIM Listing

Read more
3 May 2016 07:42

Evgen Pharma Doses First Patients In Phase 2 SFX-01 Trial For Stroke

Read more
2 Mar 2016 09:44

Evgen Pharma Gets Approvals To Begin Phase II SFX-01 Trial

Read more
19 Jan 2016 15:32

CORRECT: DIRECTOR DEALINGS: Evgen Pharma Directors Buy 136,000 Shares

Read more
19 Jan 2016 14:59

Berkeley Group non-exec picks up first shares

(ShareCast News) - First Derivatives non-executive director David Anderson offloaded 5,000 shares in the software and consulting firm at 1,541p each. The sale brought his interest in the company down to 120,000 shares, or 0.5% of the issued share capital. Elsewhere, Berkeley Group non-executive dir

Read more
19 Jan 2016 09:51

DIRECTOR DEALINGS: Evgen Pharma Directors Bought 136,000 Shares

Read more
4 Jan 2016 11:52

Evgen appoints new Chief Medical Officer

(ShareCast News) - Evgen Pharma announced the appointment of a new Chief Medical Officer on Monday. The AIM-listed clinical stage drug development company, focused on the treatment of cancer and neurological conditions, said Dr Hamina Patel would be appointed to the post. Dr Patel was described by

Read more
7 Dec 2015 09:20

Evgen Says "Very Encouraged" By SFX-01 Development In Maiden Results

Read more
26 Nov 2015 09:45

BROKER RATINGS SUMMARY: OneSavings Upped To Buy, Aldermore Cut To Hold

Read more
23 Nov 2015 09:04

Evgen Pharma Buys Licensing Rights For Range Of Compounds In Spain

Read more
21 Oct 2015 11:24

Evgen Pharma Joins AIM With GBP7.0 Million Raised In IPO (ALLIPO)

Read more
9 Sep 2011 16:55

London close: Stocks dive on euro worries

The volatility continued heading into the weekend and stocks were nursing hefty losses at the close of play. The resignation of European Central Bank official Juergen Stark brought the Eurozone crisis into focus. Stark, a German, like many of his compatriots is unhappy about the Bank's policy of b

Read more
9 Sep 2011 12:33

Broker tips: Home Retail, Premier Farnell, Evolution

Singer Capital Markets has slashed its target price for FTSE 250 retailer Home Retail Group by 29%, after the group's first half results showed continued tough trading at Argos and a challenging second quarter for Homebase. "Whilst not as bad as feared the continued weakness of trade at Argos and o

Read more
9 Sep 2011 12:11

Broker snap: Peel Hunt ups target for Evolution after Investec offer

Following Investec's recommended offer for Evolution, Peel Hunt has raised its target price on the investment banking and stockbroking firm from 86p to 100p to reflect the offer price. Investec, the FTSE 100 South African banking titan, announced on Friday morning that it has made a recommended off

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.